{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:48:44Z","timestamp":1794854924065,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12891-015-0516-3","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T23:55:09Z","timestamp":1426031709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from Rheumatoid arthritis patients"],"prefix":"10.1186","volume":"16","author":[{"given":"Alicia","family":"Santos Savio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cecilia","family":"Machado Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Chico Capote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamilet","family":"Miranda Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunier","family":"Rodr\u00edguez Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Bringas P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Est\u00e9vez del Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo E","family":"Guillen Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397\u2013440.","journal-title":"Annu Rev Immunol"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB Mcinnes","year":"2007","unstructured":"Mcinnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429\u201342.","journal-title":"Nat Rev Immunol"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0140-6736(88)90185-7","volume":"ii","author":"JA Eastgate","year":"1988","unstructured":"Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis and osteoarthritis. Lancet. 1988;ii:706\u20139.","journal-title":"Lancet"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/ard.53.8.521","volume":"53","author":"NG Arvidsson","year":"1994","unstructured":"Arvidsson NG, Gudbj\u00f6rnsson B, Elfman L, Ryden AC, T\u00f6tterman T, H\u00e4llgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994;53:521\u20134.","journal-title":"Ann Rheum Dis"},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/ard.49.9.676","volume":"49","author":"CL Westacott","year":"1990","unstructured":"Westacott CL, Whicher JT, Barnes IC, Thompson D, Swan AJ, Diepppe PA. Synovial fluid concentrations of five different cytokines in rheumatic diseases. Ann Rheum Dis. 1990;49:676\u201381.","journal-title":"Ann Rheum Dis"},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.49.9.665","volume":"49","author":"C Tetta","year":"1990","unstructured":"Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis. 1990;49:665\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"516_CR7","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.62.suppl_2.ii13","volume":"62","author":"MC Hochberg","year":"2003","unstructured":"Hochberg MC, Tracey JK, Hawkins-Holts M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl):ii13\u20136.","journal-title":"Ann Rheum Dis"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.clinthera.2012.02.014","volume":"34","author":"I Navarro-Mill\u00e1n","year":"2012","unstructured":"Navarro-Mill\u00e1n I, Singh J, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34:788\u2013802. e3.","journal-title":"Clin Ther"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11 Suppl 1","author":"A Rubbert-Roth","year":"2009","unstructured":"Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1:S1.","journal-title":"Arthritis Res Ther"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987\u201397.","journal-title":"Lancet"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm0296-175","volume":"2","author":"IB McInnes","year":"1996","unstructured":"McInnes IB, Al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med. 1996;2:175\u201382.","journal-title":"Nat Med"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2567.2008.02878.x","volume":"126","author":"R R\u00fcckert","year":"2009","unstructured":"R\u00fcckert R, Brandt K, Ernst M, Marienfeld K, Csernok E, Metzler C, et al. Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis? Immunology. 2009;126:63\u201373.","journal-title":"Immunology"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.4049\/jimmunol.170.4.2106","volume":"170","author":"S Ferretti","year":"2003","unstructured":"Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. Il-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol. 2003;170:2106\u201312.","journal-title":"J Immunol"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm0297-189","volume":"3","author":"IB Mcinnes","year":"1997","unstructured":"Mcinnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-\u03b1 production in rheumatoid arthritis. Nat Med. 1997;3:189\u201395.","journal-title":"Nat Med"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/eji.200737229","volume":"37","author":"K Yoshihara","year":"2007","unstructured":"Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y. IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol. 2007;37:2744\u201352.","journal-title":"Eur J Immunol"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/art.21731","volume":"54","author":"ME Miranda-Carus","year":"2006","unstructured":"Miranda-Carus ME, Benito-Miguel M, Balsa A, Cobo-Ib\u00e1\u00f1ez T, P\u00e9rez de Ayala C, Pascual-Salcedo D, et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum. 2006;54:1151\u201364.","journal-title":"Arthritis Rheum"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.4049\/jimmunol.173.3.1681","volume":"173","author":"E Mortier","year":"2004","unstructured":"Mortier E, Bernard J, Plet AY, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor \u03b1- chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol. 2004;173:1681\u20138.","journal-title":"J Immunol"},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R\u03b1 recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002;17:537\u201347.","journal-title":"Immunity"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1074\/jbc.M508624200","volume":"281","author":"E Mortier","year":"2006","unstructured":"Mortier E, Qu\u00e9m\u00e9ner A, Vusio P, Lorenzen I, Boublik Y, Gr\u00f6tzinger J, et al. Soluble interleukin-15 receptor \u03b1 (IL-15R\u03b1)-sushi as a selective and potent agonist of IL-15 action through IL-15R\u03b2\/\u03b3: hyperagonist IL-15\u2022IL-15R\u03b1 fusion proteins. J Biol Chem. 2006;281:1612\u20139.","journal-title":"J Biol Chem"},{"key":"516_CR22","doi-asserted-by":"publisher","first-page":"42192","DOI":"10.1074\/jbc.M403182200","volume":"279","author":"V Budagian","year":"2004","unstructured":"Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem. 2004;279:42192\u2013201.","journal-title":"J Biol Chem"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.4049\/jimmunol.172.7.4225","volume":"172","author":"GG Neely","year":"2004","unstructured":"Neely GG, Epelman S, Ma LL, Colarusso P, Howlett CJ, Amankwah EK, et al. Monocyte surfacebound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol. 2004;172:4225\u201334.","journal-title":"J Immunol"},{"key":"516_CR24","first-page":"943156","volume":"2012","author":"AC Machado","year":"2012","unstructured":"Machado AC, Chico A, Arrieta CA, Rodr\u00edguez Y, Garc\u00eda del Barco D, Est\u00e9vez del Toro M, et al. Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis. 2012;2012:943156.","journal-title":"Arthritis"},{"key":"516_CR25","first-page":"320","volume":"25","author":"A Santos","year":"2008","unstructured":"Santos A, Cabrales A, Reyes O, Ger\u00f3nimo H, Rodr\u00edguez Y, Garay H, et al. Identification of an interleukin-15 antagonist peptide that binds to IL-15Ra. Biotecnol Apl. 2008;25:320\u20134.","journal-title":"Biotecnol Apl"},{"key":"516_CR26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2144\/03342mt01","volume":"34","author":"AI Saeed","year":"2003","unstructured":"Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374\u20138.","journal-title":"Biotechniques"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/rheumatology\/38.3.202","volume":"38","author":"G Steiner","year":"1999","unstructured":"Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology. 1999;38:202\u201313.","journal-title":"Rheumatology"},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/art.1780400614","volume":"40","author":"H Okamoto","year":"1997","unstructured":"Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096\u2013105.","journal-title":"Arthritis Rheum"},{"key":"516_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/jbmr.5650110113","volume":"11","author":"S Kotake","year":"1996","unstructured":"Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluid from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88\u201395.","journal-title":"J Bone Miner Res"},{"key":"516_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1182\/blood-2011-10-384362","volume":"120","author":"C Bergamaschi","year":"2012","unstructured":"Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15R\u03b1 in human and mouse serum. Blood. 2012;120:e1\u20138.","journal-title":"Blood"},{"key":"516_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","volume":"7","author":"M Kapoor","year":"2011","unstructured":"Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"516_CR32","first-page":"1547","volume-title":"Kelley\u2019s Textbook of Rheumatology, vol. 1","author":"J Sellam","year":"2008","unstructured":"Sellam J, Berenbaum F. Clinical features of osteoarthritis. In: Firestein GS, editor. Kelley\u2019s Textbook of Rheumatology, vol. 1. 8th ed. Philadelphia: Saunders\/Elsevier; 2008. p. 1547\u201360.","edition":"8"},{"key":"516_CR33","doi-asserted-by":"publisher","first-page":"1040e8","DOI":"10.1016\/j.joca.2009.02.011","volume":"17","author":"CR Scanzello","year":"2009","unstructured":"Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, et al. Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage. 2009;17:1040e8.","journal-title":"Osteoarthritis Cartilage"},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1155\/2013\/176278","volume":"35","author":"JM Sun","year":"2013","unstructured":"Sun JM, Sun LZ, Liu J, Su B, Shi L. Serum interleukin-15 levels are associated with severity of pain in patients with knee osteoarthritis. Dis Markers. 2013;35:203\u20136.","journal-title":"Dis Markers"},{"key":"516_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/(SICI)1096-9896(199704)181:4<444::AID-PATH778>3.0.CO;2-O","volume":"181","author":"EW Thurkow","year":"1997","unstructured":"Thurkow EW, van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol. 1997;181:444\u201350.","journal-title":"J Pathol"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00296-001-0161-z","volume":"21","author":"AM Ortiz","year":"2002","unstructured":"Ortiz AM, Laffon EA, Gonzalez-Alvaro I. CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int. 2002;21:182\u20138.","journal-title":"Rheumatol Int"},{"key":"516_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1136\/ard.59.6.439","volume":"59","author":"AK Ulfgren","year":"2000","unstructured":"Ulfgren AK, Gr\u00f6ndal L, Lindblad S, Khademi M, Johnell O, Klareskog L, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis. 2000;59:439\u201347.","journal-title":"Ann Rheum Dis"},{"key":"516_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","volume":"34","author":"MC Hochberg","year":"2005","unstructured":"Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit\/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819\u201336.","journal-title":"Semin Arthritis Rheum"},{"key":"516_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","volume":"53","author":"YM Pers","year":"2014","unstructured":"Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology. 2014;53:76\u201384.","journal-title":"Rheumatology"},{"key":"516_CR40","first-page":"115","volume":"11","author":"A Mussi","year":"1997","unstructured":"Mussi A, Bonifati C, Carducci M, D\u2019Agosto G, Pimpinelli F, D\u2019Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11:115\u20138.","journal-title":"J Biol Regul Homeost Agents"},{"key":"516_CR41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/ard.2007.080440","volume":"67","author":"CA Wijbrandts","year":"2008","unstructured":"Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis. 2008;67:1139\u201344.","journal-title":"Ann Rheum Dis"},{"key":"516_CR42","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/rheumatology\/ken261","volume":"47","author":"MH Buch","year":"2008","unstructured":"Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw K, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology. 2008;47:1469\u201375.","journal-title":"Rheumatology"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-015-0516-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0516-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T21:05:18Z","timestamp":1747775118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-015-0516-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s12891-015-0516-3","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]},"assertion":[{"value":"9 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"51"}}